PR89720

SAN JOSE, Calif. and PUNE, India, May 25, 2021 /PRNewswire=KYODO JBN/ --

- OptraSCAN's Intelligent Tool CytoSiA – To Advance Cytology Screening Through

Unmatched Image Quality And Artificial Intelligence Based Image Analysis

Solution

    OptraSCAN® [https://www.optrascan.com/], the leading On-Demand Digital

Pathology solution provider, today announced its intelligent solution CytoSiA

(https://www.optrascan.com/solutions/cytology-analysis) for rapid yet

affordable scanning and analyzing of liquid-based cytology slides and

pap-smears. It is a complete solution consisting of OptraSCAN's digital

pathology scanner, storage, and powerful artificial intelligence (AI)

algorithms to assist pathologists and cytotechnologists in screening and

detection of cervical cancer, pre-cancerous lesions, atypical cells, and all

other cytologic categories. Multiple hospitals and pathology laboratories

globally have already installed CytoSiA and are witnessing improved patient

outcomes, increased efficiency, and productivity needed to cope with the

ever-increasing demand of cytology cases.

    "OptraSCAN is redefining cervical cancer screening by introducing CytoSiA,

[https://www.optrascan.com/solutions/cytology-analysis] it offers a plethora of

features, to effectively screen liquid-based cytology slides, and pap smears to

differentiate between normal and abnormal cervical cells using Bethesda

classifications on normal to squamous cell carcinoma (NILM/LSIL/HSIL/SCC)",

said Abhi Gholap, [https://www.optrascan.com/about-us/leadership-team] Founder

of OptraSCAN. With a range of scanning devices handling as low as 50 slides a

week to 5000 slides a week at an extremely affordable price," he further added.

OptraSCANS's digital scanners can scan cytology slides of size 15x15 mm area at

40x magnification in less than 60 seconds while generating the highest quality

image. CytoSia incorporates patented technology- composite imaging

(https://www.optrascan.com/news/140-optrascan-to-expand-into-digital-cytology-so

lution) which finds all pixels in focus from various Z plane images and

stitches back to create a single layer composite image. This composite imaging

technology is considerably efficient as compared to traditional Z-Stacking

Technology. It allows for rapid and precise screening of the entire slide

within seconds. This level of precision and quality is imperative for analyzing

the samples. Furthermore, it presents to the screener images of fields that

would be essential in providing a cytological interpretation, place them into

categories, and filter out the redundancies.

    CytoSiA [https://www.optrascan.com/solutions/cytology-analysis] when used

as a companion diagnostic tool, it notifies pathologists when inconsistencies

between their interpretation and the AI algorithm's findings are observed,

offering a safeguard against error or misinterpretation, while also improving

overall care quality.

    Features of CytoSiA:

- Automated computation of sample adequacy for the whole slide cytology image

- Identification of abnormal cells and other entities based on morphological

features and AI-based classification using Bethesda scoring

- Identification of reactive, endometrial, actinomyces, candida, clue cells,

trichomonas vaginalis, and herpes entities

- Identification of entities including blood, inflammation, and lubricant

    "AI-based image analysis requires images that are of superior quality,"

said Dr Aparna Joshi, Medical Director, at OptraSCAN. "Our team has developed

an intelligent imaging technology that transforms physical glass cytology

slides into digital images with exceptional clarity. Advanced image analysis

and standardization are now achievable with this quality of digitization," she

further added.

    Contact OptraSCAN [info@optrascan.com]

    About OptraSCAN, Inc:

    OptraSCAN® are pioneers in the On-Demand Digital Pathology® System, focused

on delivering fully integrated, affordable solutions that will maximize your

return on investment and improve the performance of your pathology services. An

ISO 13485 certified company and CE marked whole slide scanners for IVD use,

OptraSCAN is working to eliminate the barriers to "Go Digital" no matter the

size of the pathology lab, the lab's throughput or global location.

    OptraSCAN's end-to-end digital pathology solution provides effective

acquisition of whole slide images, viewing, storing, real-time sharing,

reporting and AI & ML based Image analysis solutions via On-Demand or outright

purchase model. Follow Us on LinkedIn

[https://in.linkedin.com/company/optra-scan] and Twitter

[https://mobile.twitter.com/optrascan].

    Media Inquiries Contact:

    Anjana Athanikar

    Manager – Marketing Communications  

    a.athanikar@optraventures.com

    Logo: https://mma.prnewswire.com/media/1517923/Optra_Scan_Logo.jpg  

    Photo: https://mma.prnewswire.com/media/1517924/OptraScan_CytoSiA.jpg

    Source: OptraSCAN Inc.